共查询到20条相似文献,搜索用时 0 毫秒
1.
2.
马斌 《计算机科学技术学报》2010,25(1):107-123
Mass spectrometry is an analytical technique for determining the composition of a sample. Recently it has become a primary tool for protein identification and quantification, and post translational modification characterization in proteomics research. Both the size and the complexity of the data produced by this experimental technique impose great computational challenges in the data analysis. This article reviews some of these challenges and serves as an entry point for those who want to study the area in ... 相似文献
3.
Mass spectrometry offers the potential of acquiring high resolution data depicting the functional status of a group of healthy or diseased individuals, according to different conditions. As most of the drugs are currently targeting proteins, proteomics has a dual value, both in the discovery of new molecules as therapeutic targets, but also as a methodology to perform high throughput drug profiling. As there is an evident need for drugs to be improved in terms of efficacy, a mechanistic insight for downstream effectors can be valuable in order to predict side effects and resistance mechanisms. Recently developed assays, like thermal proteome profiling enables comprehensive drug target profiling and is, therefore, of high value in drug discovery. In this review, a systematic literature search is conducted and the most prominent proteomics studies as implicated in assisting drug discovery and development is presented. Focus is placed on investigations that are closer to implementation, therefore particular emphasis is given in studies conducted in human diseased population and further verified in vitro or in vivo. 相似文献
4.
5.
Ricardo Cambraia Parreira Diana Paola Gmez‐Mendoza Itamar Couto Guedes de Jesus Rafael Pereira Lemos Anderson Kennedy Santos Cristiana Perdigo Rezende Henrique Csar Pereira Figueiredo Mauro Cunha Xavier Pinto Frank Kjeldsen Silvia Guatimosim Rodrigo Ribeiro Resende Thiago Verano‐Braga 《Proteomics. Clinical applications》2020,14(4)
6.
《Proteomics. Clinical applications》2018,12(5)
Purpose: Retinoblastoma (RB) is a pediatric ocular cancer which is caused due to the aberrations in the RB1 gene. The changes in the membrane proteomics would help in understanding the development of the retinoblastoma and could identify candidates for biomarkers and therapy. Experimental design: Quantitative proteomics is performed on the enriched membrane fractions from pooled normal retina (n = 5) and pooled retinoblastoma tissues (n = 5). The proteins are tryptic‐digested and tagged with iTRAQ labels. Orbitrap mass spectrometry is used to analyze and quantify the deregulated membrane proteins involved in the RB tumor progression. Immunohistochemistry (IHC) is used to further validate few of the differentially expressed proteins. Results: A total of 3122 proteins are identified of which, 663 proteins are found to be deregulated with ≥two fold change in the RB tumor compared to the retina. 282 proteins are upregulated and 381 are downregulated with ≥2 peptide identifications. Bioinformatic analysis revealed that, most of the proteins are involved in the transport, cellular communication, and growth. Overexpression of lamin B1 (LMNB1) and transferrin receptor (TFRC) are observed in RB tumors using IHC. Conclusion and clinical relevance: The present study, is the first comprehensive quantitative membrane proteomic atlas of the differentially regulated proteins in RB compared to the retina. LMNB1 and TFRC could be potential biomarkers for this childhood cancer. 相似文献
7.
8.
Shuang Yang;Chengbin Zhou;Lei Zhang;Yueting Xiong;Yongtao Zheng;Liuguan Bian;Xiaohui Liu; 《Proteomics. Clinical applications》2024,18(2):2300010
Despite recent advancements in our understanding of driver gene mutations and heterogeneity within brain tumors, whether primary or metastatic (also known as secondary), our comprehension of proteomic changes remains inadequate. The aim of this study is to provide an informative source for brain tumor researches, and distinguish primary brain tumors and secondary brain tumors from extracranial origins based on proteomic analysis. 相似文献
9.
10.
11.
PRIME: A Mass Spectrum Data Mining Tool for <Emphasis Type="Italic">De Nova</Emphasis> Sequencing and PTMs Identification 下载免费PDF全文
De novo sequencing is one of the most promising proteomics techniques for identification of protein posttranslation modifications (PTMs) in studying protein regulations and functions. We have developed a computer tool PRIME for identification of b and y ions in tandem mass spectra, a key challenging problem in de novo sequencing. PRIME utilizes a feature that ions of the same and different types follow different mass-difference distributions to separate b from y ions correctly. We have formulated the problem as a graph partition problem. A linear integer-programming algorithm has been implemented to solve the graph partition problem rigorously and efficiently. The performance of PRIME has been demonstrated on a large amount of simulated tandem mass spectra derived from Yeast genome and its power of detecting PTMs has been tested on 216 simulated phosphopeptides. 相似文献
12.
13.
14.
15.
16.
The recently implemented General Data Protection Regulation (GDPR) has promising attributes for ensuring the protection of personal data collected and processed for clinical proteomic investigations. However, there exist ever increasing alarming concerns regarding its implications upon the future of clinical proteomics research both within and beyond the European Union. The main issues of concern regard GDPR legislative requirements for informed consent for study subjects’ data collection and processing, data anonymization, and data storage and/or sharing, particularly in research areas which readily utilize databanks and biobanks, such as clinical proteomics investigations. The potential impacts of the aforementioned issues upon on‐going and future clinical proteomics investigations are detailed, whilst recommendations for potentially resolving these emerging issues are proposed. Consensus between government, legislative, and research stakeholders, as well as impact assessments of final measures to be applied for medical research, is necessary so as to ensure the favorable perpetuation of clinical proteomics investigations and subsequent impact upon optimal patient health. 相似文献
17.
18.
19.